Nanoplate based digital PCR assay for effective quantification of plasma HPV circulating tumor DNA
A blood test tracking HPV DNA reliably predicted whether cervical cancer would return or stay gone, offering doctors a simpler way to monitor treatment without repeated biopsies.
A multiplex nanoplate digital PCR assay for HPV ctDNA (types 16, 18, 31) was validated in 87 cervical cancer patients, achieving 98% sensitivity and 100% specificity for pre-treatment detection. Longitudinal HPV ctDNA monitoring reliably predicted disease relapse and remission, supporting clinical translation as a minimally invasive monitoring tool.
What the study was
- Study design
- Prospective clinical validation study (registered RCT, CTRI/2020/01/022862)
- Population
- Cervical cancer patients (pre-treatment and follow-up)
- Sample size
- 87
- Category
- Early Detection
- Maturity
- Validated
- Journal
- NPJ Precision Oncology
Why it surfaced
High sensitivity/specificity validated prospective ctDNA assay for cervical cancer monitoring in registered clinical trial; ctDNA clearance predicts remission with potential to replace or complement imaging surveillance.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.